GLP1R and hydrops fetalis: Evidence from meta-analyses indicates that GLP-1 RAs consistently reduce rates of major cardiovascular events, HF hospitalizations, and kidney disease progression, with treatment effects preserved irrespective of concurrent SGLT2 inhibitor use.